US regulators, FDA have approved a new long-acting, injectable antipsychotic with a range of dosing strengths and regimens designed to address the individual treatment requirements of patients with schizophrenia.
The merger of Alkermes and Elan Corp’s drug technology unit has now been completed, following the approval of the merger by Alkermes shareholders on the 8th September 2011. The new entity, which will be known as Alkermes plc, will be headquartered in Dublin. With operations based in Athlone, they have approximately 450 employees based in
